Prognostic Impact of Loss of SETD2 in Clear Cell Renal Cell Carcinoma
To evaluate the prognostic impact of immunohistochemical expression of SETD2 in patients with clear cell renal cell carcinoma (ccRCC). A total of 662 patients with primary or metastatic ccRCC were evaluated. Two genitourinary pathologist reviewed all of the cases for uniform reclassification and det...
Gespeichert in:
| Veröffentlicht in: | Clinical genitourinary cancer 2021-08, Vol.19 (4), p.339-345 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 345 |
|---|---|
| container_issue | 4 |
| container_start_page | 339 |
| container_title | Clinical genitourinary cancer |
| container_volume | 19 |
| creator | Santos, Victor Espinheira da Costa, Walter Henriques Bezerra, Stephania Martins da Cunha, Isabela Werneck Nobre, Jayme Quirino Caon Brazão, Eder Silveira Meduna, Rafael Ribeiro Rocha, Mauricio Murce Fornazieri, Lucas Zequi, Stenio de Cassio |
| description | To evaluate the prognostic impact of immunohistochemical expression of SETD2 in patients with clear cell renal cell carcinoma (ccRCC).
A total of 662 patients with primary or metastatic ccRCC were evaluated. Two genitourinary pathologist reviewed all of the cases for uniform reclassification and determined the selection of the most representative tumor areas for construction of the tissue microarray (TMA).
SETD2 nuclear staining showed that 101 areas (15.3%) had negative expression, and 561 areas (84,7%) had positive expression of SETD2. The protein expression of SETD2 was associated with clinical stage (P < .001), pathological stage (P < .001), tumor size (P < .001), perinephric fat invasion (P < .001), Eastern Cooperative Oncology Group status (P = .004), surgery type (P < .001), International Society of Urologic Pathologists grade (P < .001), and tumor necrosis (P < .001). SETD2 influenced disease-specific survival (DSS) and overall survival (OS). DSS rates in patients with positive and negative expression of SETD2 were 90.2% and 58.4%, respectively (P < .001). OS rates in patients with positive and negative expression of SETD2 were 87% and 55.4%, respectively (P < .001). In a multivariate Cox analysis, low SETD2 expression was an independent predictor of DSS (hazard ratio [HR], 1.690; 95% confidence interval [CI], 1.0582.700; P = .031) and OS (HR, 1.641; 95% CI, 1.039-2.593; P = .037).
Our study showed that the negative expression of SETD2 was associated with a worse prognosis, and it was an independent predictor of survival in patients with ccRCC. We believe that the protein expression of SETD2 is an important biomarker in the management of patients with ccRCC.
The purpose of this study was to evaluate the prognostic impact of immunohistochemical expression of SETD2 in 662 patients with clear cell renal cell carcinoma (ccRCC). In a multivariate Cox analysis, negative SETD2 expression was an independent predictor of disease-specific survival and overall survival. The protein expression of SETD2 is an important biomarker in the management of patients with ccRCC. |
| doi_str_mv | 10.1016/j.clgc.2021.03.003 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2511896443</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1558767321000665</els_id><sourcerecordid>2511896443</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-a99e704e7f8bf35e49d8c3230cdc62c29f6f962b1f7253970c3a85e5be4d98c53</originalsourceid><addsrcrecordid>eNp9kEtLxDAUhYMovv-AC-nSTWuS27QJuJE6PmBA8bEOmdtbydDHmHQE_70dRl26umdxzuGej7EzwTPBRXG5zLB9x0xyKTIOGeewww6FAZ3yQsvdSSul07Io4YAdxbjkPFei5PvsAECD4WAO2ewpDO_9EEePyUO3cjgmQ5PMhxg392X2eiMT3ydVSy4kFbVt8ky9a7eycgF9P3TuhO01ro10-nOP2dvt7LW6T-ePdw_V9TxFUMWYOmOo5DmVjV40oCg3tUaQwLHGQqI0TdGYQi5EU0oFpuQITitSC8pro1HBMbvY9q7C8LGmONrOR5xecT0N62ilEkKbIs9hssqtFcM0JlBjV8F3LnxZwe0Gn13aDT67wWc52AnfFDr_6V8vOqr_Ir-8JsPV1kDTyk9PwUb01CPVPhCOth78f_3fTT1-aQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2511896443</pqid></control><display><type>article</type><title>Prognostic Impact of Loss of SETD2 in Clear Cell Renal Cell Carcinoma</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Santos, Victor Espinheira ; da Costa, Walter Henriques ; Bezerra, Stephania Martins ; da Cunha, Isabela Werneck ; Nobre, Jayme Quirino Caon ; Brazão, Eder Silveira ; Meduna, Rafael Ribeiro ; Rocha, Mauricio Murce ; Fornazieri, Lucas ; Zequi, Stenio de Cassio</creator><creatorcontrib>Santos, Victor Espinheira ; da Costa, Walter Henriques ; Bezerra, Stephania Martins ; da Cunha, Isabela Werneck ; Nobre, Jayme Quirino Caon ; Brazão, Eder Silveira ; Meduna, Rafael Ribeiro ; Rocha, Mauricio Murce ; Fornazieri, Lucas ; Zequi, Stenio de Cassio</creatorcontrib><description><![CDATA[To evaluate the prognostic impact of immunohistochemical expression of SETD2 in patients with clear cell renal cell carcinoma (ccRCC).
A total of 662 patients with primary or metastatic ccRCC were evaluated. Two genitourinary pathologist reviewed all of the cases for uniform reclassification and determined the selection of the most representative tumor areas for construction of the tissue microarray (TMA).
SETD2 nuclear staining showed that 101 areas (15.3%) had negative expression, and 561 areas (84,7%) had positive expression of SETD2. The protein expression of SETD2 was associated with clinical stage (P < .001), pathological stage (P < .001), tumor size (P < .001), perinephric fat invasion (P < .001), Eastern Cooperative Oncology Group status (P = .004), surgery type (P < .001), International Society of Urologic Pathologists grade (P < .001), and tumor necrosis (P < .001). SETD2 influenced disease-specific survival (DSS) and overall survival (OS). DSS rates in patients with positive and negative expression of SETD2 were 90.2% and 58.4%, respectively (P < .001). OS rates in patients with positive and negative expression of SETD2 were 87% and 55.4%, respectively (P < .001). In a multivariate Cox analysis, low SETD2 expression was an independent predictor of DSS (hazard ratio [HR], 1.690; 95% confidence interval [CI], 1.0582.700; P = .031) and OS (HR, 1.641; 95% CI, 1.039-2.593; P = .037).
Our study showed that the negative expression of SETD2 was associated with a worse prognosis, and it was an independent predictor of survival in patients with ccRCC. We believe that the protein expression of SETD2 is an important biomarker in the management of patients with ccRCC.
The purpose of this study was to evaluate the prognostic impact of immunohistochemical expression of SETD2 in 662 patients with clear cell renal cell carcinoma (ccRCC). In a multivariate Cox analysis, negative SETD2 expression was an independent predictor of disease-specific survival and overall survival. The protein expression of SETD2 is an important biomarker in the management of patients with ccRCC.]]></description><identifier>ISSN: 1558-7673</identifier><identifier>EISSN: 1938-0682</identifier><identifier>DOI: 10.1016/j.clgc.2021.03.003</identifier><identifier>PMID: 33839039</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Biomarkers, Tumor ; Carcinoma, Renal Cell - genetics ; Carcinoma, Renal Cell - surgery ; Histone-Lysine N-Methyltransferase - genetics ; Humans ; Kidney ; Kidney Neoplasms - genetics ; Kidney Neoplasms - surgery ; Molecular marker ; Prognosis ; Renal cell carcinoma ; SETD2</subject><ispartof>Clinical genitourinary cancer, 2021-08, Vol.19 (4), p.339-345</ispartof><rights>2021</rights><rights>Copyright © 2021. Published by Elsevier Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356t-a99e704e7f8bf35e49d8c3230cdc62c29f6f962b1f7253970c3a85e5be4d98c53</citedby><cites>FETCH-LOGICAL-c356t-a99e704e7f8bf35e49d8c3230cdc62c29f6f962b1f7253970c3a85e5be4d98c53</cites><orcidid>0000-0002-9762-7170 ; 0000-0001-8645-9960 ; 0000-0001-6502-4300 ; 0000-0002-0357-8612 ; 0000-0002-5448-6857 ; 0000-0003-1897-8085</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33839039$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Santos, Victor Espinheira</creatorcontrib><creatorcontrib>da Costa, Walter Henriques</creatorcontrib><creatorcontrib>Bezerra, Stephania Martins</creatorcontrib><creatorcontrib>da Cunha, Isabela Werneck</creatorcontrib><creatorcontrib>Nobre, Jayme Quirino Caon</creatorcontrib><creatorcontrib>Brazão, Eder Silveira</creatorcontrib><creatorcontrib>Meduna, Rafael Ribeiro</creatorcontrib><creatorcontrib>Rocha, Mauricio Murce</creatorcontrib><creatorcontrib>Fornazieri, Lucas</creatorcontrib><creatorcontrib>Zequi, Stenio de Cassio</creatorcontrib><title>Prognostic Impact of Loss of SETD2 in Clear Cell Renal Cell Carcinoma</title><title>Clinical genitourinary cancer</title><addtitle>Clin Genitourin Cancer</addtitle><description><![CDATA[To evaluate the prognostic impact of immunohistochemical expression of SETD2 in patients with clear cell renal cell carcinoma (ccRCC).
A total of 662 patients with primary or metastatic ccRCC were evaluated. Two genitourinary pathologist reviewed all of the cases for uniform reclassification and determined the selection of the most representative tumor areas for construction of the tissue microarray (TMA).
SETD2 nuclear staining showed that 101 areas (15.3%) had negative expression, and 561 areas (84,7%) had positive expression of SETD2. The protein expression of SETD2 was associated with clinical stage (P < .001), pathological stage (P < .001), tumor size (P < .001), perinephric fat invasion (P < .001), Eastern Cooperative Oncology Group status (P = .004), surgery type (P < .001), International Society of Urologic Pathologists grade (P < .001), and tumor necrosis (P < .001). SETD2 influenced disease-specific survival (DSS) and overall survival (OS). DSS rates in patients with positive and negative expression of SETD2 were 90.2% and 58.4%, respectively (P < .001). OS rates in patients with positive and negative expression of SETD2 were 87% and 55.4%, respectively (P < .001). In a multivariate Cox analysis, low SETD2 expression was an independent predictor of DSS (hazard ratio [HR], 1.690; 95% confidence interval [CI], 1.0582.700; P = .031) and OS (HR, 1.641; 95% CI, 1.039-2.593; P = .037).
Our study showed that the negative expression of SETD2 was associated with a worse prognosis, and it was an independent predictor of survival in patients with ccRCC. We believe that the protein expression of SETD2 is an important biomarker in the management of patients with ccRCC.
The purpose of this study was to evaluate the prognostic impact of immunohistochemical expression of SETD2 in 662 patients with clear cell renal cell carcinoma (ccRCC). In a multivariate Cox analysis, negative SETD2 expression was an independent predictor of disease-specific survival and overall survival. The protein expression of SETD2 is an important biomarker in the management of patients with ccRCC.]]></description><subject>Biomarkers, Tumor</subject><subject>Carcinoma, Renal Cell - genetics</subject><subject>Carcinoma, Renal Cell - surgery</subject><subject>Histone-Lysine N-Methyltransferase - genetics</subject><subject>Humans</subject><subject>Kidney</subject><subject>Kidney Neoplasms - genetics</subject><subject>Kidney Neoplasms - surgery</subject><subject>Molecular marker</subject><subject>Prognosis</subject><subject>Renal cell carcinoma</subject><subject>SETD2</subject><issn>1558-7673</issn><issn>1938-0682</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kEtLxDAUhYMovv-AC-nSTWuS27QJuJE6PmBA8bEOmdtbydDHmHQE_70dRl26umdxzuGej7EzwTPBRXG5zLB9x0xyKTIOGeewww6FAZ3yQsvdSSul07Io4YAdxbjkPFei5PvsAECD4WAO2ewpDO_9EEePyUO3cjgmQ5PMhxg392X2eiMT3ydVSy4kFbVt8ky9a7eycgF9P3TuhO01ro10-nOP2dvt7LW6T-ePdw_V9TxFUMWYOmOo5DmVjV40oCg3tUaQwLHGQqI0TdGYQi5EU0oFpuQITitSC8pro1HBMbvY9q7C8LGmONrOR5xecT0N62ilEkKbIs9hssqtFcM0JlBjV8F3LnxZwe0Gn13aDT67wWc52AnfFDr_6V8vOqr_Ir-8JsPV1kDTyk9PwUb01CPVPhCOth78f_3fTT1-aQ</recordid><startdate>202108</startdate><enddate>202108</enddate><creator>Santos, Victor Espinheira</creator><creator>da Costa, Walter Henriques</creator><creator>Bezerra, Stephania Martins</creator><creator>da Cunha, Isabela Werneck</creator><creator>Nobre, Jayme Quirino Caon</creator><creator>Brazão, Eder Silveira</creator><creator>Meduna, Rafael Ribeiro</creator><creator>Rocha, Mauricio Murce</creator><creator>Fornazieri, Lucas</creator><creator>Zequi, Stenio de Cassio</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-9762-7170</orcidid><orcidid>https://orcid.org/0000-0001-8645-9960</orcidid><orcidid>https://orcid.org/0000-0001-6502-4300</orcidid><orcidid>https://orcid.org/0000-0002-0357-8612</orcidid><orcidid>https://orcid.org/0000-0002-5448-6857</orcidid><orcidid>https://orcid.org/0000-0003-1897-8085</orcidid></search><sort><creationdate>202108</creationdate><title>Prognostic Impact of Loss of SETD2 in Clear Cell Renal Cell Carcinoma</title><author>Santos, Victor Espinheira ; da Costa, Walter Henriques ; Bezerra, Stephania Martins ; da Cunha, Isabela Werneck ; Nobre, Jayme Quirino Caon ; Brazão, Eder Silveira ; Meduna, Rafael Ribeiro ; Rocha, Mauricio Murce ; Fornazieri, Lucas ; Zequi, Stenio de Cassio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-a99e704e7f8bf35e49d8c3230cdc62c29f6f962b1f7253970c3a85e5be4d98c53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Biomarkers, Tumor</topic><topic>Carcinoma, Renal Cell - genetics</topic><topic>Carcinoma, Renal Cell - surgery</topic><topic>Histone-Lysine N-Methyltransferase - genetics</topic><topic>Humans</topic><topic>Kidney</topic><topic>Kidney Neoplasms - genetics</topic><topic>Kidney Neoplasms - surgery</topic><topic>Molecular marker</topic><topic>Prognosis</topic><topic>Renal cell carcinoma</topic><topic>SETD2</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Santos, Victor Espinheira</creatorcontrib><creatorcontrib>da Costa, Walter Henriques</creatorcontrib><creatorcontrib>Bezerra, Stephania Martins</creatorcontrib><creatorcontrib>da Cunha, Isabela Werneck</creatorcontrib><creatorcontrib>Nobre, Jayme Quirino Caon</creatorcontrib><creatorcontrib>Brazão, Eder Silveira</creatorcontrib><creatorcontrib>Meduna, Rafael Ribeiro</creatorcontrib><creatorcontrib>Rocha, Mauricio Murce</creatorcontrib><creatorcontrib>Fornazieri, Lucas</creatorcontrib><creatorcontrib>Zequi, Stenio de Cassio</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical genitourinary cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Santos, Victor Espinheira</au><au>da Costa, Walter Henriques</au><au>Bezerra, Stephania Martins</au><au>da Cunha, Isabela Werneck</au><au>Nobre, Jayme Quirino Caon</au><au>Brazão, Eder Silveira</au><au>Meduna, Rafael Ribeiro</au><au>Rocha, Mauricio Murce</au><au>Fornazieri, Lucas</au><au>Zequi, Stenio de Cassio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic Impact of Loss of SETD2 in Clear Cell Renal Cell Carcinoma</atitle><jtitle>Clinical genitourinary cancer</jtitle><addtitle>Clin Genitourin Cancer</addtitle><date>2021-08</date><risdate>2021</risdate><volume>19</volume><issue>4</issue><spage>339</spage><epage>345</epage><pages>339-345</pages><issn>1558-7673</issn><eissn>1938-0682</eissn><abstract><![CDATA[To evaluate the prognostic impact of immunohistochemical expression of SETD2 in patients with clear cell renal cell carcinoma (ccRCC).
A total of 662 patients with primary or metastatic ccRCC were evaluated. Two genitourinary pathologist reviewed all of the cases for uniform reclassification and determined the selection of the most representative tumor areas for construction of the tissue microarray (TMA).
SETD2 nuclear staining showed that 101 areas (15.3%) had negative expression, and 561 areas (84,7%) had positive expression of SETD2. The protein expression of SETD2 was associated with clinical stage (P < .001), pathological stage (P < .001), tumor size (P < .001), perinephric fat invasion (P < .001), Eastern Cooperative Oncology Group status (P = .004), surgery type (P < .001), International Society of Urologic Pathologists grade (P < .001), and tumor necrosis (P < .001). SETD2 influenced disease-specific survival (DSS) and overall survival (OS). DSS rates in patients with positive and negative expression of SETD2 were 90.2% and 58.4%, respectively (P < .001). OS rates in patients with positive and negative expression of SETD2 were 87% and 55.4%, respectively (P < .001). In a multivariate Cox analysis, low SETD2 expression was an independent predictor of DSS (hazard ratio [HR], 1.690; 95% confidence interval [CI], 1.0582.700; P = .031) and OS (HR, 1.641; 95% CI, 1.039-2.593; P = .037).
Our study showed that the negative expression of SETD2 was associated with a worse prognosis, and it was an independent predictor of survival in patients with ccRCC. We believe that the protein expression of SETD2 is an important biomarker in the management of patients with ccRCC.
The purpose of this study was to evaluate the prognostic impact of immunohistochemical expression of SETD2 in 662 patients with clear cell renal cell carcinoma (ccRCC). In a multivariate Cox analysis, negative SETD2 expression was an independent predictor of disease-specific survival and overall survival. The protein expression of SETD2 is an important biomarker in the management of patients with ccRCC.]]></abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>33839039</pmid><doi>10.1016/j.clgc.2021.03.003</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-9762-7170</orcidid><orcidid>https://orcid.org/0000-0001-8645-9960</orcidid><orcidid>https://orcid.org/0000-0001-6502-4300</orcidid><orcidid>https://orcid.org/0000-0002-0357-8612</orcidid><orcidid>https://orcid.org/0000-0002-5448-6857</orcidid><orcidid>https://orcid.org/0000-0003-1897-8085</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1558-7673 |
| ispartof | Clinical genitourinary cancer, 2021-08, Vol.19 (4), p.339-345 |
| issn | 1558-7673 1938-0682 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2511896443 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Biomarkers, Tumor Carcinoma, Renal Cell - genetics Carcinoma, Renal Cell - surgery Histone-Lysine N-Methyltransferase - genetics Humans Kidney Kidney Neoplasms - genetics Kidney Neoplasms - surgery Molecular marker Prognosis Renal cell carcinoma SETD2 |
| title | Prognostic Impact of Loss of SETD2 in Clear Cell Renal Cell Carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T08%3A00%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20Impact%20of%20Loss%20of%20SETD2%20in%20Clear%20Cell%20Renal%20Cell%20Carcinoma&rft.jtitle=Clinical%20genitourinary%20cancer&rft.au=Santos,%20Victor%20Espinheira&rft.date=2021-08&rft.volume=19&rft.issue=4&rft.spage=339&rft.epage=345&rft.pages=339-345&rft.issn=1558-7673&rft.eissn=1938-0682&rft_id=info:doi/10.1016/j.clgc.2021.03.003&rft_dat=%3Cproquest_cross%3E2511896443%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2511896443&rft_id=info:pmid/33839039&rft_els_id=S1558767321000665&rfr_iscdi=true |